184 related articles for article (PubMed ID: 24619759)
21. The Prognostic Impact of CD163-Positive Macrophages in Follicular Lymphoma: A Study from the BC Cancer Agency and the Lymphoma Study Association.
Kridel R; Xerri L; Gelas-Dore B; Tan K; Feugier P; Vawda A; Canioni D; Farinha P; Boussetta S; Moccia AA; Brice P; Chavez EA; Kyle AH; Scott DW; Sanders AD; Fabiani B; Slack GW; Minchinton AI; Haioun C; Connors JM; Sehn LH; Steidl C; Gascoyne RD; Salles G
Clin Cancer Res; 2015 Aug; 21(15):3428-35. PubMed ID: 25869385
[TBL] [Abstract][Full Text] [Related]
22. Classical Hodgkin lymphoma, lymphocyte depleted type: clinicopathological analysis and prognostic comparison with other types of classical Hodgkin lymphoma.
Karube K; Niino D; Kimura Y; Ohshima K
Pathol Res Pract; 2013 Apr; 209(4):201-7. PubMed ID: 23478005
[TBL] [Abstract][Full Text] [Related]
23. CD163 versus CD68 in tumor associated macrophages of classical Hodgkin lymphoma.
Harris JA; Jain S; Ren Q; Zarineh A; Liu C; Ibrahim S
Diagn Pathol; 2012 Jan; 7():12. PubMed ID: 22289504
[TBL] [Abstract][Full Text] [Related]
24. Association of the numbers of CD163(+) cells in lesional skin and serum levels of soluble CD163 with disease progression of cutaneous T cell lymphoma.
Sugaya M; Miyagaki T; Ohmatsu H; Suga H; Kai H; Kamata M; Fujita H; Asano Y; Tada Y; Kadono T; Okochi H; Sato S
J Dermatol Sci; 2012 Oct; 68(1):45-51. PubMed ID: 22884782
[TBL] [Abstract][Full Text] [Related]
25. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
[TBL] [Abstract][Full Text] [Related]
26. CSF1R Protein Expression in Reactive Lymphoid Tissues and Lymphoma: Its Relevance in Classical Hodgkin Lymphoma.
Martín-Moreno AM; Roncador G; Maestre L; Mata E; Jiménez S; Martínez-Torrecuadrada JL; Reyes-García AI; Rubio C; Tomás JF; Estévez M; Pulford K; Piris MA; García JF
PLoS One; 2015; 10(6):e0125203. PubMed ID: 26066800
[TBL] [Abstract][Full Text] [Related]
27. Independent prognostic impact of tumour-infiltrating macrophages in early-stage Hodgkin's lymphoma.
Gotti M; Nicola M; Lucioni M; Fiaccadori V; Ferretti V; Sciarra R; Costanza M; Bono E; Molo S; Maffi A; Croci GA; Varettoni M; Frigeni M; Pascutto C; Arcaini L; Bonfichi M; Paulli M; Cazzola M
Hematol Oncol; 2017 Sep; 35(3):296-302. PubMed ID: 27060262
[TBL] [Abstract][Full Text] [Related]
28. The prognostic value of intraepithelial and stromal innate immune system cells in non-small cell lung carcinoma.
Al-Shibli K; Al-Saad S; Donnem T; Persson M; Bremnes RM; Busund LT
Histopathology; 2009 Sep; 55(3):301-12. PubMed ID: 19723145
[TBL] [Abstract][Full Text] [Related]
29. Meta-analysis of the prognostic and clinical value of tumor-associated macrophages in adult classical Hodgkin lymphoma.
Guo B; Cen H; Tan X; Ke Q
BMC Med; 2016 Oct; 14(1):159. PubMed ID: 27745550
[TBL] [Abstract][Full Text] [Related]
30. Expression of the colony stimulating factor-1 receptor (c-fms product) by cells at the human uteroplacental interface.
Jokhi PP; Chumbley G; King A; Gardner L; Loke YW
Lab Invest; 1993 Mar; 68(3):308-20. PubMed ID: 8450649
[TBL] [Abstract][Full Text] [Related]
31. The role of CD68+ macrophage in classical Hodgkin lymphoma patients from Egypt.
Mohamed O; El Bastawisy A; Allahlobi N; Abdellateif MS; Zekri ARN; Shaarawy S; Korany Z; Mohanad M; Bahnassy AA
Diagn Pathol; 2020 Feb; 15(1):10. PubMed ID: 32019558
[TBL] [Abstract][Full Text] [Related]
32. Tumor-associated macrophages and crown-like structures in adipose tissue in breast cancer.
Cha YJ; Kim ES; Koo JS
Breast Cancer Res Treat; 2018 Jul; 170(1):15-25. PubMed ID: 29468486
[TBL] [Abstract][Full Text] [Related]
33. Prognostic Value of Tumor Associated Macrophage Markers CD163 and CD68 Immunohistochemistry in Classical Hodgkin Lymphoma.
Rashed RA; Zaki MAM; Mohamed NAW; Mansou OM; Refaey FAHE
Clin Lab; 2021 May; 67(5):. PubMed ID: 33978358
[TBL] [Abstract][Full Text] [Related]
34. Tumor-promoting macrophages induce the expression of the macrophage-specific receptor CD163 in malignant cells.
Maniecki MB; Etzerodt A; Ulhøi BP; Steiniche T; Borre M; Dyrskjøt L; Orntoft TF; Moestrup SK; Møller HJ
Int J Cancer; 2012 Nov; 131(10):2320-31. PubMed ID: 22362417
[TBL] [Abstract][Full Text] [Related]
35. Ratio of M2 macrophage expression is closely associated with poor prognosis for Angioimmunoblastic T-cell lymphoma (AITL).
Niino D; Komohara Y; Murayama T; Aoki R; Kimura Y; Hashikawa K; Kiyasu J; Takeuchi M; Suefuji N; Sugita Y; Takeya M; Ohshima K
Pathol Int; 2010 Apr; 60(4):278-83. PubMed ID: 20403029
[TBL] [Abstract][Full Text] [Related]
36. Detection of M2-macrophages in uveal melanoma and relation with survival.
Bronkhorst IH; Ly LV; Jordanova ES; Vrolijk J; Versluis M; Luyten GP; Jager MJ
Invest Ophthalmol Vis Sci; 2011 Feb; 52(2):643-50. PubMed ID: 20811059
[TBL] [Abstract][Full Text] [Related]
37. Cancer-associated fibroblasts and CD163-positive macrophages in oral squamous cell carcinoma: their clinicopathological and prognostic significance.
Fujii N; Shomori K; Shiomi T; Nakabayashi M; Takeda C; Ryoke K; Ito H
J Oral Pathol Med; 2012 Jul; 41(6):444-51. PubMed ID: 22296275
[TBL] [Abstract][Full Text] [Related]
38. Refined prognostic role of CD68-positive tumor macrophages in the context of the cellular micromilieu of classical Hodgkin lymphoma.
Tzankov A; Matter MS; Dirnhofer S
Pathobiology; 2010; 77(6):301-8. PubMed ID: 21266828
[TBL] [Abstract][Full Text] [Related]
39. Age and Expression of CD163 and Colony-Stimulating Factor 1 Receptor (CD115) Are Associated With the Biological Behavior of Central Giant Cell Granuloma.
Kahn A; Chaushu G; Ginene L; Vered M
J Oral Maxillofac Surg; 2017 Jul; 75(7):1414-1424. PubMed ID: 28161361
[TBL] [Abstract][Full Text] [Related]
40. Expression of Epstein-Barr virus latent membrane protein-1 in Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma: associations with presenting features, serum interleukin 10 levels, and clinical outcome.
Herling M; Rassidakis GZ; Medeiros LJ; Vassilakopoulos TP; Kliche KO; Nadali G; Viviani S; Bonfante V; Giardini R; Chilosi M; Kittas C; Gianni AM; Bonadonna G; Pizzolo G; Pangalis GA; Cabanillas F; Sarris AH
Clin Cancer Res; 2003 Jun; 9(6):2114-20. PubMed ID: 12796376
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
